Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

Abstract

Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients’ quality of life.

Keywords

• exanthema
• toxicity
• egfr tyrosine kinase inhibitor
• quality of life
• chemotherapy